WALTHAM, Mass., February 5, 2020 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Stewart Campbell, Ph.D., Senior Vice President, Research & Development, will present a translational overview of Axial’s Autism program at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ (CCTRND) Emerging Management Therapies for Childhood Neurodevelopment Disorders Inaugural Scientific Symposium on Thursday, February 6, 2020 at 11:00 AM AEST (Wednesday, February 5, 2020, 7:00 PM ET) at the Queensland Children’s Hospital in South Brisbane, Queensland, Australia.
About Axial Biotherapeutics
Axial Biotherapeutics is a clinical stage biotechnology company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of central nervous system (CNS) and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.
Stern Investor Relations, Inc.